AAAAAA

   
Results: 1-24 |
Results: 24
Singlet oxygen inhibits agonist-induced P-selectin expression and formation of platelet aggregates
Authors: Stief, TW Jeske, WP Walenga, J Schultz, C Kretschmer, V Fareed, J
Citation: Tw. Stief et al., Singlet oxygen inhibits agonist-induced P-selectin expression and formation of platelet aggregates, CL APPL T-H, 7(3), 2001, pp. 219-224
Evaluation of a new point of care heparin test for cardiopulmonary bypass:the TAS heparin management test
Authors: Wallock, M Jeske, WP Bakhos, M Walenga, JM
Citation: M. Wallock et al., Evaluation of a new point of care heparin test for cardiopulmonary bypass:the TAS heparin management test, PERFUSION-U, 16(2), 2001, pp. 147-153
Inhibition of tissue factor-activated platelets by low-molecular-weight heparins and glycoprotein IIb/IIIa receptor antagonist
Authors: Ahmad, S Jeske, WP Ma, Q Walenga, JM Fareed, J
Citation: S. Ahmad et al., Inhibition of tissue factor-activated platelets by low-molecular-weight heparins and glycoprotein IIb/IIIa receptor antagonist, THROMB RES, 102(2), 2001, pp. 143-151
Mechanisms of venous and arterial thrombosis in heparin-induced thrombocytopenia
Authors: Walenga, JM Jeske, WP Messmore, HL
Citation: Jm. Walenga et al., Mechanisms of venous and arterial thrombosis in heparin-induced thrombocytopenia, J THROMB TH, 10, 2000, pp. S13-S20
Statin drugs and dietary isoprenoids as antithrombotic agents
Authors: Fenton, JW Shen, GX Minnear, FL Brezniak, DV Jeske, WP Walenga, JM Bognacki, JJ Ofosu, FA Hassouna, HI
Citation: Jw. Fenton et al., Statin drugs and dietary isoprenoids as antithrombotic agents, HEMAT ONCOL, 14(2), 2000, pp. 483
Letter to the editor - The authors' response
Authors: Izban, KF Lietz, HW Hoppensteadt, DA Jeske, WP Fareed, J Bakhos, M Walenga, JM
Citation: Kf. Izban et al., Letter to the editor - The authors' response, SEM THROMB, 26(4), 2000, pp. 440-440
Abciximab treatment in vitro after aspirin treatment in vivo has additive effects on platelet aggregation, ATP release, and P-selectin expression
Authors: Scazziota, A Altman, R Rouvier, J Gonzalez, C Ahmed, Z Jeske, WP Walenga, JM Fareed, J
Citation: A. Scazziota et al., Abciximab treatment in vitro after aspirin treatment in vivo has additive effects on platelet aggregation, ATP release, and P-selectin expression, THROMB RES, 100(6), 2000, pp. 479-488
Human anti-heparin-platelet factor 4 antibodies are capable of activating primate platelets: Towards the development of a HIT model in primates
Authors: Ahmad, S Jeske, WP Walenga, JM Aldabbagh, A Iqbal, O Fareed, J
Citation: S. Ahmad et al., Human anti-heparin-platelet factor 4 antibodies are capable of activating primate platelets: Towards the development of a HIT model in primates, THROMB RES, 100(1), 2000, pp. 47-54
Pathophysiology of heparin-induced thrombocytopenia clinical and diagnostic implications - A review
Authors: Fabris, F Ahmad, S Cella, G Jeske, WP Walenga, JM Fareed, J
Citation: F. Fabris et al., Pathophysiology of heparin-induced thrombocytopenia clinical and diagnostic implications - A review, ARCH PATH L, 124(11), 2000, pp. 1657-1666
Simultaneous monitoring of argatroban and its major metabolite using an HPLC method: Potential clinical applications
Authors: Ahmad, S Ahsan, A George, M Iqbal, O Jeske, WP McKenna, R Lewis, BE Walenga, JM Fareed, J
Citation: S. Ahmad et al., Simultaneous monitoring of argatroban and its major metabolite using an HPLC method: Potential clinical applications, CL APPL T-H, 5(4), 1999, pp. 252-258
Synthetic pentasaccharides do not cause platelet activation by antiheparin-platelet factor 4 antibodies
Authors: Ahmad, S Jeske, WP Walenga, JM Hoppensteadt, DA Wood, JJ Herbert, JM Messmore, HL Fareed, J
Citation: S. Ahmad et al., Synthetic pentasaccharides do not cause platelet activation by antiheparin-platelet factor 4 antibodies, CL APPL T-H, 5(4), 1999, pp. 259-266
Heparin-induced thrombocytopenia: Clinical considerations of alternative anticoagulation with various glycosaminoglycans and thrombin inhibitors
Authors: Haas, S Walenga, JM Jeske, WP Fareed, J
Citation: S. Haas et al., Heparin-induced thrombocytopenia: Clinical considerations of alternative anticoagulation with various glycosaminoglycans and thrombin inhibitors, CL APPL T-H, 5(1), 1999, pp. 52-59
Laboratory diagnosis of heparin-induced thrombocytopenia
Authors: Walenga, JM Jeske, WP Fasanella, AR Wood, JJ Ahmad, S Bakhos, M
Citation: Jm. Walenga et al., Laboratory diagnosis of heparin-induced thrombocytopenia, CL APPL T-H, 5, 1999, pp. S21-S27
Functional heterogeneity of antiheparin-platelet factor 4 antibodies: Implications in the pathogenesis of the HIT syndrome
Authors: Ahmad, S Walenga, JM Jeske, WP Cella, G Fareed, J
Citation: S. Ahmad et al., Functional heterogeneity of antiheparin-platelet factor 4 antibodies: Implications in the pathogenesis of the HIT syndrome, CL APPL T-H, 5, 1999, pp. S32-S37
Soluble adhesion molecules in the HIT syndrome: Pathophysiologic role and therapeutic modulation
Authors: Fareed, J Walenga, JM Hoppensteadt, DA Jeske, WP Ahmad, S Lietz, H McKenna, R Messmore, HL Haas, S
Citation: J. Fareed et al., Soluble adhesion molecules in the HIT syndrome: Pathophysiologic role and therapeutic modulation, CL APPL T-H, 5, 1999, pp. S38-S44
Heparin-induced thrombocytopenic potential of GAG and non-GAG-based antithrombotic agents
Authors: Jeske, WP Jay, AM Haas, S Walenga, JM
Citation: Wp. Jeske et al., Heparin-induced thrombocytopenic potential of GAG and non-GAG-based antithrombotic agents, CL APPL T-H, 5, 1999, pp. S56-S62
Acquired defects of fibrinolysis associated with thrombosis
Authors: Fareed, J Hoppensteadt, DA Jeske, WP Ahmad, S Bick, RL
Citation: J. Fareed et al., Acquired defects of fibrinolysis associated with thrombosis, SEM THROMB, 25(4), 1999, pp. 367-374
Selectins in the HIT syndrome: Pathophysiologic role and therapeutic modulation
Authors: Fareed, J Walenga, JM Hoppensteadt, DA Jeske, WP Lietz, H Ahmad, S Callas, D Messmore, HL Haas, S
Citation: J. Fareed et al., Selectins in the HIT syndrome: Pathophysiologic role and therapeutic modulation, SEM THROMB, 25, 1999, pp. 37-42
Laboratory tests for the diagnosis of heparin-induced thrombocytopenia
Authors: Walenga, JM Jeske, WP Fasanella, AR Wood, JJ Bakhos, M
Citation: Jm. Walenga et al., Laboratory tests for the diagnosis of heparin-induced thrombocytopenia, SEM THROMB, 25, 1999, pp. 43-49
Comparison of two PF4/heparin ELISA assays for the laboratory diagnosis ofheparin-induced thrombocytopenia
Authors: Izban, KF Lietz, HW Hoppensteadt, DA Jeske, WP Fareed, J Bakhos, M Walenga, JM
Citation: Kf. Izban et al., Comparison of two PF4/heparin ELISA assays for the laboratory diagnosis ofheparin-induced thrombocytopenia, SEM THROMB, 25, 1999, pp. 51-56
Heparin-induced thrombocytopenia: The role of platelet activation and therapeutic implications
Authors: Haas, S Walenga, JM Jeske, WP Fareed, J
Citation: S. Haas et al., Heparin-induced thrombocytopenia: The role of platelet activation and therapeutic implications, SEM THROMB, 25, 1999, pp. 67-75
Clinical experience with combined treatment of thrombin inhibitors and GPIIb IIIa inhibitors in patients with HIT
Authors: Walenga, JM Jeske, WP Wallis, DE Bakhos, M Lewis, BE Leya, F Fareed, J
Citation: Jm. Walenga et al., Clinical experience with combined treatment of thrombin inhibitors and GPIIb IIIa inhibitors in patients with HIT, SEM THROMB, 25, 1999, pp. 77-81
Laboratory monitoring of pentasaccharide in a dog model of hemodialysis
Authors: Hoppensteadt, DA Jeske, WP Walenga, JM Fu, KD Yang, LH Ing, TS Herbert, JM Fareed, J
Citation: Da. Hoppensteadt et al., Laboratory monitoring of pentasaccharide in a dog model of hemodialysis, THROMB RES, 96(2), 1999, pp. 115-124
Laboratory tests for heparin-induced thrombocytopenia: A multicenter study
Authors: Walenga, JM Jeske, WP Wood, JJ Ahmad, S Lewis, BE Bakhos, M
Citation: Jm. Walenga et al., Laboratory tests for heparin-induced thrombocytopenia: A multicenter study, SEM HEMATOL, 36(1), 1999, pp. 22-28
Risultati: 1-24 |